Compassionate Use of Dupilumab
NCT04776694 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2025-09-22
Summary
Provide Compassionate Use of Dupilumab
Conditions
- Type 2 Inflammatory Disorders
Interventions
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Safety and Efficacy of Abatacept in IgG4-Related Disease
NCT03669861 ·Status: COMPLETED ·Phase: PHASE2
-
Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy
NCT00258180 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
NCT06293053 ·Status: RECRUITING ·Phase: PHASE3
-
Rituximab for Anti-cytokine Autoantibody-Associated Diseases
NCT01842386 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency
NCT03733067 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
NCT02959944 ·Status: COMPLETED ·Phase: PHASE3
-
Neutralizing Interferon Type 1 in Hidradenitis Suppurativa
NCT07067099 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers
NCT04601844 ·Status: COMPLETED ·Phase: PHASE1
-
Compassionate Use of Evinacumab
NCT06500598 ·Status: APPROVED_FOR_MARKETING
-
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
NCT04206553 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Rituximab in the Treatment of Patients With Bullous Pemphigoid
NCT00286325 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Abatacept in Juvenile Dermatomyositis
NCT02594735 ·Status: COMPLETED ·Phase: PHASE4
-
Interleukin-1 Trap to Treat Autoinflammatory Diseases
NCT00094900 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)
NCT01066598 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab in Interstitial Pneumonitis
NCT02251964 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)
NCT06253507 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa
NCT05040698 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy
NCT04779957 ·Status: COMPLETED ·Phase: PHASE2
-
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
NCT06325709 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease
NCT03327857 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
NCT02810444 ·Status: COMPLETED ·Phase: PHASE3
-
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
NCT04925375 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
NCT05444530 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
NCT07287644 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196 ·Status: RECRUITING ·Phase: PHASE3